Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Nexsen Limited ( (AU:NXN) ) is now available.
Nexsen Limited has announced the commencement of a clinical trial for its GBS Rapid Sensor, branded as StrepSure®, in collaboration with RMIT University. This trial marks a significant milestone in validating their next-generation diagnostic platform, which aims to transform maternal health by providing rapid, lab-grade detection of Group B Streptococcus in expectant mothers. The trial, led by renowned maternal-fetal medicine expert Professor Lisa Hui, is being conducted at Northern Hospital, Epping, and is expected to facilitate early market penetration by the second half of 2026. Nexsen is also pursuing regulatory approvals and planning for scaled manufacturing and global market rollout, with the potential to replace current care standards and improve outcomes for mothers and infants worldwide.
More about Nexsen Limited
Nexsen Limited is a nano-biotechnology company that specializes in developing innovative point-of-care diagnostic platforms. The company focuses on maternal diagnostics and aims to provide advanced diagnostic tools for healthcare markets globally.
Average Trading Volume: 3,050,430
See more data about NXN stock on TipRanks’ Stock Analysis page.